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Background: We report the first results of a randomized trial assessing a new oral aminobisphosphonate,
ibandronate, in patients with bone metastases from breast cancer.
Patients and methods: Patients (n = 435) received placebo, or oral ibandronate 20 mg or 50 mg once-daily
for 96 weeks. The primary efficacy measure was the number of 12-week periods with new bone complications
[skeletal morbidity period rate (SMPR)]. Multivariate Poisson regression analysis assessed the relative risk
reduction of skeletal-related events. Secondary efficacy analyses included bone pain and analgesic use. Adverse
events were monitored.
Results: SMPR was significantly reduced with oral ibandronate [placebo 1.2, 20 mg group 0.97 (P = 0.024),
50 mg group 0.98 (P = 0.037)]. Ibandronate 50 mg significantly reduced the need for radiotherapy (P = 0.005
versus placebo). The relative risk of skeletal events was reduced by 38% (20 mg dose) and 39% (50 mg dose)
versus placebo (P = 0.009 and P = 0.005). The tolerability profile of ibandronate was similar to placebo.
Conclusions: Oral ibandronate is an effective and well-tolerated treatment for metastatic bone disease. The
50 mg dose is being further evaluated in clinical trials, and this dose was recently approved in the European
Union for the prevention of skeletal events in patients with breast cancer and bone metastases.
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Introduction
An estimated 65–75% of women with breast cancer will go on to
develop bone metastases [1, 2], with complications including
pathological fractures, spinal cord compression and hypercalcemia
[3]. Two-thirds of patients with bone metastases experience severe
pain and disability [4], with detrimental effects on quality of life
that may persist throughout the duration of cancer therapy and
beyond.
Bisphosphonates effectively reduce the risk of skeletal compli-
cations from metastatic bone disease, and are currently considered
to be the standard of care for most patients [5–12]. Current treat-
ment typically involves intravenous (i.v.) pamidronate [5], or
recently approved zoledronate [10]. Yet while i.v. administration
may be appropriate for certain patients, the need for regular clinic
visits is a distinct disadvantage, reducing treatment convenience.
For most patients, oral bisphosphonate therapy would be preferable,
allowing convenient self-administration at home.
Clodronate is the only bisphosphonate currently available as an
oral formulation for the treatment of metastatic bone disease.
Clodronate is less effective against skeletal complications than i.v.
pamidronate [7] and its use can lead to gastrointestinal side-effects
such as diarrhea [13–17]. Because of the low potency of clodronate
[18], 1040 or 1600 mg/day is administered over multiple doses,
with a large tablet size that may be difficult for some patients to
swallow [19, 20] and this may affect compliance.
Ibandronate, a highly potent, third-generation aminobisphos-
phonate, has been developed in both i.v. and oral formulations.
The results of a placebo-controlled phase III trial have shown that
i.v. ibandronate 6 mg infused every 3–4 weeks is effective at
reducing skeletal complications and alleviating bone pain in
patients with metastatic bone disease from breast cancer [21]. This





This randomized, parallel-group, double-blind, placebo-controlled multicenter
study was conducted at 68 centers in the USA, Australia, New Zealand,
Bulgaria, Russia and South Africa. Women with histologically confirmed
breast cancer and radiologically confirmed bone metastases were recruited
into the study. Patients had a World Health Organization (WHO) performance
status of 0–2, were at least 18 years of age, and provided written informed
consent. Exclusion criteria included previous treatment with bisphosphonates
or gallium nitrate within the last 6 months, life expectancy <60 weeks, hyper-
calcemia (serum calcium, albumin-corrected, ≥2.7 mmol/l); hypocalcemia
(serum calcium, albumin-corrected, ≤2.0 mmol/l), impaired renal function
(serum creatinine >3.0 mg/dl), Paget’s disease of the bone, primary hyper-
parathyroidism, known liver/brain metastases, and treatment with amino-
glycoside antibiotics within 4 weeks prior to the start of study medication.
Therapy
Subjects were randomized to receive placebo, oral ibandronate 20 mg or oral
ibandronate 50 mg once daily for up to 96 weeks. Patients were instructed to
take one tablet daily in the morning, 1 h before breakfast, but not to take the
tablet with milk, milk products or calcium tablets. To assess compliance with
therapy, patients were required to return their oral medication blister packs to
the investigator every 12 weeks. Concomitant treatments were allowed during
the study (except those specified as exclusion criteria). Randomization was
carried out according to a pre-determined randomization list based on block
randomization. Treatment was only unblinded in the case of a medical necessity
for patient management.
Assessments
Patients attended clinic visits at 4-week intervals for assessment of fractures,
episodes of radiotherapy, surgical interventions, bone pain and analgesic con-
sumption. Bone scans and X-rays of the thoracic and lumbar spine were per-
formed at baseline and weeks 24, 48, 72 and 96. Additional radiographs were
performed if necessitated by clinical symptoms. Vertebral fractures were
assessed morphometrically [22]. At each 4-weekly visit, a clinical assessment
for fractures occurring during the previous 4 weeks was performed. Episodes
of radiotherapy and surgical interventions for actual or impending fractures
were recorded by the investigator. Adverse events (AEs) were recorded
throughout the study. An AE was defined as any undesired, noxious or patho-
logical change in a patient as indicated by signs, symptoms and/or laboratory
changes that occurred in association with treatment, whether considered
related or not. An AE was considered serious if the event was fatal or acutely
life-threatening, required in-patient hospitalization (or prolonged existing-
hospitalization), resulted in persistent or significant disability or incapacity, or
resulted in malignancy or congenital malformation/anomaly. Non-serious
AEs were not graded. Based on the recommendations of the European
Committee for Proprietary Medicinal Products (CPMP), post-withdrawal
follow-up (PWFU) safety and efficacy data (i.e. for the period from study
withdrawal until death or last scheduled study visit) were also collected for the
181 patients (40%) who withdrew early (placebo group n = 69, 20 mg group
n = 56, 50 mg group n = 56) to minimize the possible effects of non-random
withdrawal from the different treatment groups.
Analysis of efficacy and safety
The primary efficacy parameter was the skeletal morbidity period rate
(SMPR), defined as the number of 12-week periods with new skeletal compli-
cations (vertebral and non-vertebral fractures, bone radiotherapy or bone
surgery), divided by the number of periods on the study. SMPR was calculated
using a ‘revised event ratio’ method [23], as described in detail elsewhere [24]:
SMPR = number of periods with new skeletal events + 1/number of 12-week
periods on study + 0.5.
Supportive analyses of the SMPR included the incidence of all new bone
events (mean number of events per patient, the mean number of periods with
events, the total number of 12-week periods with events, and the percentage of
patients with events during the study period) and time to first new bone event.
A preplanned multivariate Poisson regression analysis [25] of reductions in
skeletal related events (SREs) was also conducted to determine the risk of
developing a skeletal event during the study period while controlling for any
differences in the baseline characteristics of the three treatment groups.
At each 4-weekly visit, patients were asked to rate their bone pain on a scale
from 0 (none) to 4 (intolerable). Analgesic use was scored on a scale from 0
(none) to 6 [opiates ≥100 mg morphine (or equivalent) daily] [26]. Pain scores
and analgesic use were assessed using last observation carried forward
(LOCF) scores. Urinary excretion of calcium, phosphate and C-terminal
crosslinking telopeptide of type I collagen (CTX) were also measured as markers
of bone turnover.
Statistics
A closed-test procedure was applied on the primary end point to adjust for the
multiple tests comparing the various treatments. A global null hypothesis was
tested in a first step at the two-sided α-level of 5% using the non-parametric
Jonckheere–Terpstra test [27, 28]. In case this trend test on placebo, lower
dose and higher dose groups showed significance, all pairwise comparisons
between treatments were performed using the Wilcoxon rank sum test again at
two-sided α-levels of 5%. This test procedure guarantees multiple α-levels of
5%. For any test, the maximum of the P-values from the global test and the test
itself is regarded as an overall or adjusted P-value. Tests on the components of
the primary end point were considered exploratory and no further α-adjustment
was made. A logistic regression continuation model was assumed for sample
size calculations. Based on historical data and assuming a 15% increase in
patients with no event period, a sample size of 68 patients per group was calcu-
lated given a two-sided test level of 5% and a power of 80%. The sample size
was set to 100 randomized patients per group to allow for a drop-out rate of
∼30%. The trial was designed so that the statistical analysis was powered for
SMPR of the primary end point (i.e. sum of the individual SMPR com-
ponents). The Poisson regression model was employed to determine the rela-
tive risk (RR) reduction for SREs. All efficacy analyses were conducted on the
intent-to-treat population (all patients randomized to study groups) and
included PWFU data for the primary end point SMPR. Evaluation of safety
was based on all randomized patients who had received at least one dose of
study drug with at least one follow-up assessment.
Ethics
The study was performed in accordance with the principles of the Declaration
of Helsinki, the Guidelines on Good Clinical Practice and local medicines
legislation in place at the time of study initiation. Informed consent was
obtained for all subjects.
Results
Patients
A total of 435 patients were randomized to treatment and included
in the intention-to-treat (ITT) analysis (Figure 1). Patient demo-
graphic and baseline characteristics are shown in Table 1. The
ibandronate 50 mg group had a lower percentage of patients with
a WHO status of 2 (10.8%) compared with the 20 mg (19.4%) and
placebo (15.4%) groups, and the ibandronate 20 mg group had a
relatively low percentage of patients with at least 2 years since
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time of diagnosis to study initiation (17.4%) compared with the
50 mg or placebo groups (25.0% and 28.0%, respectively).
The median time on study was similar for the placebo, ibandronate
20 mg and ibandronate 50 mg groups (69.7, 72.3 and 73.3 weeks,
respectively), as was the percentage of early withdrawals (62.2%,
61.8% and 57.4%). The most common reasons for early with-
drawal were malignancy progression (placebo: 19.6%; ibandronate
20 mg: 18.8%, ibandronate 50 mg: 8.8%), other AEs (14.0%,
11.1% and 11.5%), death (9.8%, 11.8% and 13.5%) or personal
reasons (8.4%, 12.5% and 10.1%, respectively) (Table 2). None of
the patients discontinued treatment due to difficulty in swallowing
the placebo or ibandronate tablets.
Efficacy
Skeletal events. Both active treatment groups achieved a statistic-
ally significant reduction in mean SMPR including PWFU data
(global P-value versus placebo, 0.044) (Table 2). This reduction
was due primarily to a decrease in the incidence of events requiring
radiotherapy with ibandronate, which reached statistical signifi-
cance for the 50 mg dose (P = 0.005 versus placebo). Other com-
ponents of the SMPR (vertebral and non-vertebral fractures, bone
events requiring surgery) were similar between the ibandronate
and placebo groups (Table 3).
Compared with placebo, oral ibandronate significantly reduced
the mean number of new bone events and the mean number of
measurement periods with events per patient, the total number of
periods with events, and the percentage of patients with events
(Table 4). Poisson regression analysis revealed a statistically
significant reduction in the RR of SREs with ibandronate com-
pared with placebo (20 mg dose RR 0.62, P = 0.009; 50 mg dose
RR 0.61, P = 0.005) (Table 4).
Time from randomization to first new bone event was delayed
in the ibandronate groups (20 mg dose 76 weeks, 50 mg dose 54
weeks) compared with placebo (48 weeks), although this effect
did not reach statistical significance (global comparison P = 0.297).
Bone pain and analgesic use. From baseline to study end point,
LOCF bone pain scores increased by +0.21 in the placebo group,
compared with a reduction of –0.06 with 20 mg ibandronate
(P = 0.071) and a slight increase of +0.03 in the 50 mg group
(P = 0.201). Mean analgesic score was higher in the placebo group
than for either active treatment group (change from base-
line; placebo = 0.96, ibandronate 20 mg = 0.43, ibandronate
50 mg = 0.73). The difference was statistically significant for the
ibandronate 20 mg group (P = 0.006 versus placebo), and
approached significance for the 50 mg group (P = 0.074 versus
placebo).
Biochemical markers of bone turnover. At end point, the median
urinary creatinine-corrected calcium concentration was increased
by 32% in the placebo group compared with a 25% decrease with
20 mg ibandronate and a 42% decrease in the 50 mg group.
Creatinine-corrected urinary phosphate concentrations increased
in all three treatment groups. Patients on ibandronate had signifi-
cantly lower CTX values than patients in the placebo groups
(median change from baseline: –39% ibandronate 20 mg; –55%
ibandronate 50 mg, +47% placebo, P <0.0001). In addition, the
decrease in CTX values for the 50 mg group was significantly
lower than the 20 mg group (P = 0.0006).
Safety
Oral ibandronate was well tolerated. Overall, the incidence of AEs
with oral ibandronate was similar to placebo. As expected for a
population of patients with advanced cancer, most patients
(95.8%) reported at least one AE during the course of the study.
Over half of the patients (57.3%) experienced serious AEs, most
commonly malignancy progression (placebo, 44.1% of patients;
20 mg group, 47.9%; 50 mg group, 36.1%), spontaneous bone
fracture (placebo, 5.6% of patients; 20 mg group, 3.5%; 50 mg
group, 2.0%) and bone pain (placebo, 3.5% of patients; 20 mg
group, 1.4%; 50 mg group, 4.8%). There were no significant
differences between treatment groups in frequency or type of
other serious AEs.
Figure 1. Flow diagram of the study population.
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Treatment-related AEs were reported slightly more frequently
with ibandronate (placebo, 21.7%; ibandronate 20 mg, 26.4%;
ibandronate 50 mg, 27.9%) The incidence of treatment-related
nausea, hypocalcemia and abdominal pain was also slightly
higher with ibandronate than with placebo. Approximately 10%
of patients in each group experienced treatment-related upper
gastrointestinal AEs (Table 5). Six patients withdrew due to
esophagitis and dyspepsia (one from the placebo group, three
from the 20 mg group and two from the 50 mg group).
The incidence of renal AEs was not significantly different
across groups: 4.2% with placebo, 3.5% with ibandronate 20 mg
and 6.8% with ibandronate 50 mg. Only one patient withdrew
from the study due to a renal AE (a 92-year-old woman receiving
ibandronate 50 mg who developed azotemia).
Table 1. Baseline demographics and disease characteristics of patients
aInput variables for the Poisson multivariate analysis model.
bPlacebo, n = 106; ibandronate 20 mg, n = 109; ibandronate 50 mg, n = 113.
cPlacebo, n = 112; ibandronate 20 mg, n = 110; ibandronate 50 mg, n = 115.
dPlacebo, n = 141; ibandronate 20 mg, n = 143; ibandronate 50 mg, n = 147.
eHistory of ≥1 fracture due to metastatic bone disease prior to randomization.
SD, standard deviation; WHO, World Health Organization.
Placebo (n = 143) Ibandronate 20 mg (n = 144) Ibandronate 50 mg (n = 148)
Age, yearsa
Median 57 56 57
Range 31–83 30–82 29–92
Sex/race
Female, n (%) 143 (100) 144 (100) 148 (100)
Caucasian, n (%) 127 (88.8) 126 (87.5) 130 (87.8)
Time from breast cancer diagnosis, yearsb
Median 4.23 3.7 3.33
Range 0.07–23.98 0.05–19.29 0.05–24.16
Time from metastatic bone disease diagnosis, yearsc
Median 0.59 0.35 0.4
Range 0.04–23.73 0.02–5.95 0.04–15.46
Any blastic lesions, n (%) 33 (23) 23 (16) 31 (21)
Any mixed lesions, n (%) 11 (8) 14 (10) 21 (14)
Performance status, n (%)a
WHO grade 0 or 1 122 (84.6) 117 (80.5) 132 (89.2)
WHO grade 2 21 (15.4) 27 (19.4) 16 (10.8)
Ongoing use of cytotoxic drugs, n (%) 46 (32.2) 50 (34.7) 58 (39.2)
Estrogen/progesterone receptor status, n (%)a,d
Positive for either or both 52 (36.4) 59 (41.0) 63 (42.6)
Negative 14 (9.8) 18 (12.5) 10 (6.8)
Unknown 75 (52.4) 66 (45.8) 74 (50.0)
Pain scorea
Mean 1.23 1.34 1.30
SD 0.81 0.82 0.84
Analgesic scorea
Mean 1.29 1.46 1.49
SD 1.61 1.66 1.69
Presence of at least one lesion
>1 cm, n (%)a 41 (32) 55 (44) 47 (36)
No previous chemotherapy, n (%)a 95 (67) 91 (64) 94 (64)
Narcotic analgesic use, n (%) 77 (53.8) 94 (65.3) 85 (57.4)
Prior fractures at baseline, n (%)a,e 63 (44.1) 71 (49.3) 67 (45.3)
747
During the course of the study, 65 patients died. The incidence
of death was similar across the treatment groups (placebo 11.2%,
ibandronate 20 mg 16%, ibandronate 50 mg 17.7%). In most cases
(83%), death was due to malignancy progression and there were
no treatment-related deaths.
Discussion
The results of this study clearly demonstrate that oral ibandronate
effectively reduces the incidence of new skeletal events in women
with breast cancer and bone metastases. Although the study was not
powered to detect statistical significance on individual components
of the SMPR, the most marked effect of ibandronate treatment
was observed on the need for bone radiotherapy, which is considered
to be an important sequela of bone metastases. The reduction in
the need for radiotherapy was highly statistically significant for
oral ibandronate 50 mg. A similar, statistically significant reduction
in overall SMPR and SMPR for radiotherapy has also been demon-
strated with i.v. ibandronate 6 mg infused every 3–4 weeks, in a
randomized clinical trial of patients with metastatic breast cancer
[21].
A pre-planned Poisson regression analysis of the SREs was
conducted to reflect the impact of treatment on skeletal morbidity
while controlling for differences between groups at baseline such
as bone pain score and the presence of fractures. The results
revealed a highly statistically significant (P = 0.0005) RR reduc-
tion for both ibandronate doses of 39% (20 mg) and 38% (50 mg).
These RR reductions are comparable with that provided by i.v.
ibandronate 6 mg (40% reduction versus placebo, P = 0.0033)
[21].
Direct comparisons between bisphosphonates are difficult
because of differences in the parameters used to assess skeletal
events (SMPR versus skeletal morbidity rate). Previous studies of
other bisphosphonates have assessed drug efficacy using the skel-
etal morbidity rate. However, this methodology involves multiple
counting of events that are closely related and consequently may
overestimate treatment outcomes. The use of the SMPR in our
study provides a more conservative estimate of drug efficacy by




Ibandronate 20 mg 
(n = 144)
Ibandronate 50 mg 
(n = 148)
Malignancy progression reported as an AE, n (%) 28 (19.6) 27 (18.8) 13 (8.8)
Other AEs, n (%) 20 (14.0) 16 (11.1) 17 (11.5)
Death, n (%) 14 (9.8) 17 (11.8) 20 (13.5)
Personal reasons, n (%) 12 (8.4) 18 (12.5) 15 (10.1)
Lost to follow-up, n (%) 6 (4.2) 4 (2.8) 8 (5.4)
Non-compliance, n (%) 2 (1.4) 2 (1.4) 4 (2.8)
Total, n (%) 89 (62.2) 89 (61.8) 85 (57.4)
Table 3. SMPR analyses (including PWFU data)
aJonckheere–Terpstra method, global P-value versus placebo.
bWilcoxon rank sum test, P-value versus placebo.
PWFU, post-withdrawal follow-up; SMPR, skeletal morbidity period rate.
Placebo 
(n = 143)
Ibandronate 20 mg 
(n = 144)




All new bone events (SMPR) 1.20 0.97 0.98 0.044
P = 0.024b P = 0.037b
Vertebral fractures 0.51 0.52 0.52 0.730
P = 0.315b P = 0.739b
Non-vertebral fractures 0.52 0.54 0.54 0.887
P = 0.596b P = 0.890b
Events requiring radiotherapy 0.99 0.81 0.77 0.004
P = 0.082b P = 0.005b
Events requiring surgery 0.44 0.50 0.43 0.643
P = 0.738b P = 0.644b
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not counting an event more than once because it occurred over a
number of weeks.
In this study, bone pain scores with ibandronate were lower than
with placebo throughout the treatment period (approaching stat-
istical significance for the 20 mg group, P = 0.071), and were
accompanied by a significant reduction in analgesic use (P = 0.006).
Although reductions in bone pain from skeletal metastases have
been demonstrated in clinical studies of other bisphosphonates
[10–12, 19, 30], ibandronate is the only bisphosphonate shown to
maintain bone pain reductions below baseline for 2 years [24].
Oral ibandronate was well tolerated in the current study. The
incidence of treatment-related AEs was only slightly higher in the
active treatment groups and the pattern of events was as expected
for bisphosphonates [31]. Although slightly more patients in the
50 mg group experienced treatment-related upper gastrointestinal
adverse events than in the 20 mg group, the number of patients
who discontinued treatment because of these adverse events was
similar in all three study groups. The incidence of gastrointestinal
events with ibandronate was less than that reported with oral
clodronate (particularly for diarrhea) in clinical studies [13,14,17].
Approximately 60% of patients withdrew from our study before
96 weeks. Although a high proportion of drop-outs may distort the
results, this drop-out rate is somewhat lower than those observed
with pamidronate. In the study by Hortobagyi et al., ∼75% of
patients on pamidronate withdrew before 2 years [9].
Although the two oral doses of ibandronate demonstrated com-
parable efficacy on the primary end point in the current study, the
50 mg dose demonstrated a greater effect on the individual end
points of the SMPR (particularly radiotherapy). A pooled analysis
of data from this and a second multicenter study with an identical
design has also shown greater effects on skeletal complications
and symptoms with the 50 mg dose than with the 20 mg dose
[32–34]. The superiority of the 50 mg dose is further supported by
the results of a phase II dosing finding study [35] and pre-clinical
Table 4. Analyses of overall bone events
aJonckheere–Terpstra method, global P-value versus placebo.
bWilcoxon rank sum test, P-value versus placebo.
cPoisson regression analysis, P-value versus placebo.
All new bone events Placebo
 (n = 143)
Ibandronate 20 mg 
(n = 144)




Mean number of events per patient 2.23 1.36 1.43 0.017
P = 0.001b P = 0.014b
Relative risk reduction by Poisson model 38% 39%
P = 0.009c P = 0.005c
Mean number of measurement periods with events 1.27 0.79 0.84 0.017
P = 0.002b P = 0.014b
Total number of periods with events 182 114 125 0.017
P = 0.002b P = 0.014b
Percentage of patients with events 61.5 46.5 52.0 0.036
P = 0.011b P = 0.102b




Ibandronate 20 mg 
(n = 144)
Ibandronate 50 mg 
(n = 147)
Abdominal pain 2 (1.4%) 1 (0.7%) 5 (3.4%)
Dyspepsia 11 (7.7%) 12 (8.3%) 15 (10.2%)
Nausea 3 (2.1%) 8 (5.6%) 7 (4.8%)
Esophagitis 2 (1.4%) 2 (1.4%) 4 (2.7%)
Nausea and vomiting 3 (2.1%) 0 2 (1.4%)
Flatulence 3 (2.1) 0 1 (0.7%)
Diarrhea 2 (1.4%) 1 (0.7%) 1 (0.7%)
Hypocalcemia 6 (4.2%) 9 (6.3%) 10 (6.8%)
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data showing that administration of ibandronate 50 mg daily given
30 min before food provides comparable bone surface exposure to
a 6 mg i.v. dose administered every 28 days (F. Hoffmann-
LaRoche Ltd, unpublished data). The use of the 50 mg dose helps
to ensure adequate dosing of ibandronate under ‘real-world’ situ-
ations, where patients may not always comply with recommended
fasting periods (thus minimizing the impact of food intake on drug
efficacy). The 50 mg dose is being further evaluated in clinical
trials, and this dose was recently approved in the European Union
for the prevention of skeletal events in patients with breast cancer
and bone metastases.
The availability of ibandronate as a highly effective and well-
tolerated oral bisphosphonate allows flexibility in the choice of
dosing regimen, so that patients may receive i.v. or oral therapy
while in hospital, followed by oral therapy in the outpatient
setting. Self-administration of a single daily dose of therapy might
improve treatment convenience and compliance. Oral therapy
eliminates the need to visit hospital solely for i.v. bisphosphonate
therapy. This would be of particular benefit in patients who are not
currently receiving, or have completed, i.v. chemotherapy. The
convenience and compliance benefits of oral treatment may
encourage patients to remain on bisphosphonate therapy for
longer periods. Supporting this, 42% of patients receiving oral
ibandronate 50 mg in this study completed the 96-week study
period, compared with 18% for i.v. ibandronate 6 mg in another
phase III trial with a similar study design [21].
Oral ibandronate may also prove to be cost-effective in the
treatment of metastatic bone disease. Economic analyses have
shown that existing i.v. bisphosphonates are associated with rela-
tively high costs in relation to clinical benefit [36], with adminis-
tration contributing considerably to the overall cost of treatment
[37].
In conclusion, once-daily treatment with oral ibandronate is an
effective treatment for metastatic bone disease from breast cancer,
and offers the additional benefits of treatment tolerability and con-
venience. Ibandronate appears to possess equivalent efficacy to
i.v. bisphosphonates and therefore represents an important clinical
advance in metastatic bone disease management.
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